Gazzard, Brian; Hill, Andrew; Anceau, Anne - In: Applied Health Economics and Health Policy 9 (2011) 4, pp. 217-223
Background: In virologically suppressed patients, switching to darunavir/ritonavir (DRV/r) monotherapy maintains HIV RNA suppression, and could also lower treatment costs. Objective: The purpose of this analysis was to calculate the potential cost savings from the use of DRV/r monotherapy in the...
